Long-term efficacy and safety of etrasimod for ulcerative colitis: results from the open-label extension of the OASIS study

(1) University Hospitals Leuven,Leuven,Belgium

(2) Hospital Clínic de Barcelona, IDIBAPS, CIBERehd,Barcelona,Spain

(3) Virginia Mason Medical Center,Seattle,United States

(4) Lorraine University, INSERM U 954,Vandoeuvre-lès-Nancy,France

(5) Arena Pharmaceuticals,San Diego,United States

(6) Icahn School of Medicine at Mount Sinai,New York,United States

(7) University of California San Diego,La Jolla,United States

This item was part of the IBD I (Posters) session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019